Clinicians have a new first-line standard for advanced bladder cancer, according to an international phase 3 study, EV302, presented at the 2023 annual congress of the European Society for Medical Oncology (ESMO; abstract LBA6).
Median overall survival (OS) with the antibody–drug conjugate enfortumab vedotin-ejfv (Padcev, Astellas Pharma) plus pembrolizumab (Keytruda, Merck) was 31.5 months compared with 16.1 months with chemotherapy.
Thomas Powles, MRCP, MD, a professor of genitourinary